Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy

This is particularly of interest considering the rapidly advancing technical possibilities, both in imaging and in the treatment of prostate cancer, since this enables an earlier and more individual intervention in the case of recurrence.

cancer
lymph node metastases
prostatectomy
immunological adjuvant
hormone therapy
  • 0 views
  • 19 Feb, 2024
bpMRI and Risk Based Shared Clinical Decision Making in Prostate Cancer Diagnosis

Therefore, the primary objective of this trial is to compare if there is a difference between significant cancer detection rate in men undergoing prostate biopsies after MRI scan compared to men undergoing post-MRI prostate biopsies only after a shared decision-making based on prostate cancer risk estimation. The trial will enrol …

digital rectal examination
cancer diagnosis
biopsy of prostate
  • 0 views
  • 19 Feb, 2024
The Impact of Low Pressure Pneumo in RARP II

The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RARP).

prostatectomy
  • 0 views
  • 19 Feb, 2024
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

progressive disease
prostate cancer
darolutamide
atezolizumab
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

cancer
prostate cancer
enzalutamide
combined modality therapy
prostatic neoplasm
  • 0 views
  • 19 Feb, 2024
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

prostate cancer
darolutamide
gonadotropin releasing hormone
adenocarcinoma
hormone therapy
  • 0 views
  • 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

progressive disease
dexamethasone
bone scan
gonadotropin releasing hormone
neutrophil count
  • 0 views
  • 19 Feb, 2024
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

adenocarcinoma of prostate
stereotactic body radiation therapy
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.

hypofractionated radiation therapy
ct scan
white blood cell count
bone metastases
digital rectal examination
  • 0 views
  • 19 Feb, 2024